Well, that's an important point for all of us old-timers. You should view this as a happy curiosity. Spontaneous Remissions happen usually within the first three months -- that's what they used to say, anyway. After that with each passing day the chances of a reprieve get less and less. So they make the distinction between acute tinnitus and chronic tinnitus.Yes, they did. They took anyone into that trial that had it less than a year.
It is intended to treat hearing loss, so if it works as intended, maybe it would help with tinnitus.does anyone know if the OTO-825 gene therapy treatment can help tinnitus?
Absolutely yes—Phase 2 results alone will take a year to be released. Then factor in the time it takes for Phase 3 to start and then the time it takes for the drug to be commercialized if all is successful.By the time OTO-313 comes out, we will all be out of the one-year window?
1 year window is there to increase chances of OTO-313 to succeed. It does not mean it won't work beyond 1 year window, we simply don't know.By the time OTO-313 comes out, we will all be out of the one-year window?
I would take an injection if it lasted for months and no harm done lol.Stock price is probably part of an ETF, everything ripped today.
Not that Otonomy isn't a good gamble buy before the study is done.
Remember temporary improvements don't mean much, we get that with steroids.
The real data comes on at the follow up, 1/2 a year later at the least.
It was oversold, which is why it jumped. If you look at the chart over the past month, you'll see it's gone down like ~30%.Has there been an announcement or write up in the financial press on Otonomy's stock price increase? Is it related to some positive trial result?
Also, does anyone know if the OTO-825 gene therapy treatment can help tinnitus?
They are not sure. For this phase they will only test in people with an early onset, in the next phases they may increase the time of tinnitus onset.Was there anything in the presentation about the theory that it will help in just the early onset? Or any idea if it can help people who have had tinnitus for longer?
Regarding OTO-313, I don't understand the part about "testing longer period of time (3-4 months)".Otonomy gave a virtual presentation today at the HC Wainwright Investment Conference. For anyone interested I took the following notes:
OTO-313
- They've tightened up the entry requirements (no severe hearing loss patients, patients must have tinnitus for 2 months).
- They're testing for a longer period (3-4 months). They think 1 dose may have the potential to cure some people.
- If there is success in the Phase II trial it can possibly serve as a pivotal trial. (2 pivotal trials are typically needed for FDA approval)
OTO-413
There was no discussion on OTO-6XX (probably due to time), and only a few brief words on OTO-825 (also most likely due to time). Overall Dr Weber seemed pretty enthusiastic. The idea of going straight into a Phase II/III seemed kind of exciting.
- Many people in the study have hearing aids but don't use them because they don't help them.
- The interviewer asked them about Frequency Therapeutics' FX-322 data vs their OTO-413 data, they said their data is much stronger. They also talked up the importance of words in quiet vs words in noise.
- The interviewer asked them if they can go straight into Phase 3 if there's success in their extended Phase I/II trial. They responded that if the data is compelling they can enter into a Phase II/III trial.
If I'm not mistaken, tests and assessments are usually done for 2 months after exposure to the drug. This time they will be increasing that up to 4 months.Regarding OTO-313, I don't understand the part about "testing longer period of time (3-4 months)".
I thought they were giving it to everyone that have had tinnitus for less than a year?
I'm getting there... five and a half months now and not really better."Spontaneous remissions occur most often within the first three months. Then with each passing day the chances of remission get less and less. And after six months? One year? It's described as chronic tinnitus."
One interesting thing they're doing for their Phase II study is classifying the patients into 2 groups: Those who have had tinnitus for less than 6 months, and those who have had it for between 6 months and 1 year. If the 2 groups perform equally as well than it may mean this drug works for a significantly large part of the patient population. Their Phase I study only tested the drug against people who had tinnitus for less than 6 months, and I remember them saying they didn't see any tapering of benefit for the people in that study, which is why they're extending the time-frame for Phase II.Great work @patorjk.
It's great to see this thing in motion. And perhaps what makes it more exciting is that this is entrepreneurship "in motion" towards a cure or at least a therapy -- not simply a research paper. Aalthough the latter are vital too. We are missing the knowledge base and it has to be built up.
But back in the 90s when my tinnitus hit, it was already known that most remissions (cures) occurred within the first three months. As a matter of fact they used to say "Go in to the hospital straight away. Every minute counts".
So Otonomy are excited about the progress with OTO-313. If it can up the number of remissions of the onsets within the last three months, well great.
And don't forget us poor punters who have gone chronic when charity time comes around.
Ah yes. There was an elegant description back then that I made a note of.
"Spontaneous remissions occur most often within the first three months. Then with each passing day the chances of remission get less and less. And after six months? One year? It's described as chronic tinnitus."
I think that there wouldn't have been much discussion on OTO-825 or OTO-6XX because they are also actually not out of the pre-clinical work phase as yet either.There was no discussion on OTO-6XX (probably due to time), and only a few brief words on OTO-825 (also most likely due to time). Overall Dr Weber seemed pretty enthusiastic. The idea of going straight into a Phase II/III seemed kind of exciting.
My tinnitus reacts to my car's inverter when I accelerate hard (high frequency low volume whine), and to its pedestrian warning hum. Sometimes I get beeps or whistles over the charging station's sounds, too, and in very rare cases, electrical crackling, which is probably just hearing loss (I hear it at 8 and 16 kHz when I do a quiet frequency sweep, it's faint, but definitely there, present over the tone that is playing).I just feel that describes what my tinnitus is like – it sounds electrical. The other week I was in a parking house were several electrical cars was standing in a row connected to their charging boxes and the high pitch electrical sizzle sounded quite a lot like my tinnitus.
OTO-825 is in pre-IND. They had a pre-IND meeting with the FDA earlier this summer and they expect to file the IND application in the first half of 2023. If they had more money I imagine that would be happening much sooner. My assumption is that they're going to issue more stock after the results of the OTO-313 and OTO-413 trials to raise money. Though they may also do this in the run-up to the results to make sure they can survive a failure. With this additional money they'll fund the pivotal trials for those drugs as well as the Phase I trial for OTO-825.I think that there wouldn't have been much discussion on OTO-825 or OTO-6XX because they are also actually not out of the pre-clinical work phase as yet either.
My tinnitus behaves the same, when I accelerate I hear a ringing as if it was coming from the motor of my car. So weird.My tinnitus reacts to my car's inverter when I accelerate hard (high frequency low volume whine)